LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

Home・Stock List・CureVac NV

CureVac NV

Open

5.35 0.19

Buy Sell

Overview

Share price change

24h

Current

Min

5.34

Max

5.37

Key metrics
By Trading Economics
Income	-8.3M -60M
Sales	352K 1.2M
P/E Sector Avg	5.297 35.664
Profit margin	-4,816.546
Employees	825
EBITDA	-8.2M -55M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+3% upside

Dividends
By Dow Jones
Next Earnings	11 Nov 2025

Market Stats
By TradingEconomics
Market Cap	-18M 1.2B
Previous open	5.16
Previous close	5.35

Technical Score

By Trading Central

Confidence

Bullish Evidence

3.47 / 3.755 Support & Resistance

CureVac NV Chart

Past performance is not a reliable indicator of future results.

Related News

12 Jun 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 Jun 2025, 13:34 UTC

Hot Stocks

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Peer Comparison

Price change

CureVac NV Forecast

Price Target

By TipRanks

3% upside

12 Months Forecast

Average 5.5 USD 3%

High 5.5 USD

Low 5.5 USD

Based on 2 Wall Street analysts offering 12 month price targets forCureVac NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to CureVac NV - Dist in the past 3 months.

Technical Score

By Trading Central

3.47 / 3.755Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.